CRISPR Therapeutics

About:

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Website: http://crisprtx.com/

Twitter/X: crisprtx

Top Investors: New Enterprise Associates, Franklin Templeton, Versant Ventures, Bill & Melinda Gates Foundation, Vertex Pharmaceuticals

Description:

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Total Funding Amount:

$407M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)crisprtx.com

Founders:

Daniel Anderson, Emmanuelle Charpentier, Matthew Porteus, Rodger Novak, Shaun Foy

Number of Employees:

251-500

Last Funding Date:

2024-02-13

IPO Status:

Public

© 2025 bioDAO.ai